| Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. | |
| | |
MedLine Citation:
|
PMID: 19717185 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In the HORIZONS-AMI trial, patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) who were treated with the thrombin inhibitor bivalirudin had substantially lower 30-day rates of major haemorrhagic complications and net adverse clinical events than did patients assigned to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI). Here, we assess whether these initial benefits were maintained at 1 year of follow-up. METHODS: Patients aged 18 years or older were eligible for enrolment in this multicentre, open-label, randomised controlled trial if they had STEMI, presented within 12 h after the onset of symptoms, and were undergoing primary PCI. 3602 eligible patients were randomly assigned by interactive voice response system in a 1:1 ratio to receive bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; n=1800) or heparin plus a GPI (control; 60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s; n=1802). The two primary trial endpoints were major bleeding and net adverse clinical events (NACE; consisting of major bleeding or composite major adverse cardiovascular events [MACE; death, reinfarction, target vessel revascularisation for ischaemia, or stroke]). This prespecified analysis reports data for the 1-year follow-up. Analysis was by intention to treat. Patients with missing data were censored at the time of withdrawal from the study or at last follow-up. This trial is registered with ClinicalTrials.gov, number NCT00433966. FINDINGS: 1-year data were available for 1696 patients in the bivalirudin group and 1702 patients in the control group. Reasons for participant dropout were loss to follow-up and withdrawal of consent. The rate of NACE was lower in the bivalirudin group than in the control group (15.6%vs 18.3%, hazard ratio [HR] 0.83, 95% CI 0.71-0.97, p=0.022), as a result of a lower rate of major bleeding in the bivalirudin group (5.8%vs 9.2%, HR 0.61, 0.48-0.78, p<0.0001). The rate of MACE was similar between groups (11.9%vs 11.9%, HR 1.00, 0.82-1.21, p=0.98). The 1-year rates of cardiac mortality (2.1%vs 3.8%, HR 0.57, 0.38-0.84, p=0.005) and all-cause mortality (3.5%vs 4.8%, HR 0.71, 0.51-0.98, p=0.037) were lower in the bivalirudin group than in the control group. INTERPRETATION: In patients with STEMI undergoing primary PCI, anticoagulation with bivalirudin reduced the rates of net adverse clinical events and major bleeding at 1 year compared with treatment with heparin plus a GPI. This finding has important clinical implications for the selection of optimum treatment strategies for patients with STEMI. FUNDING: Cardiovascular Research Foundation, with unrestricted grant support from Boston Scientific Corporation and The Medicines Company. |
| | |
Authors:
|
Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone; |
Related Documents
:
|
12176945 - Twelve versus six months of clopidogrel to reduce major cardiac events in patients unde... 8197975 - Clinical and angiographic follow-up after coronary angioplasty in patients with two-ves... 16338255 - Benefit of clopidogrel according to timing of percutaneous coronary intervention in pat... 19753635 - Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion aft... 6996625 - Prospective, randomized, double-blind comparison of metronidazole and tobramycin with c... 22304935 - A 21-week open-label clinical trial of pregabalin as adjunctive therapy in partial seiz... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-08-28 |
Journal Detail:
|
Title: Lancet Volume: 374 ISSN: 1474-547X ISO Abbreviation: Lancet Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-05 Completed Date: 2009-10-15 Revised Date: 2010-02-04 |
Medline Journal Info:
|
Nlm Unique ID: 2985213R Medline TA: Lancet Country: England |
Other Details:
|
Languages: eng Pagination: 1149-59 Citation Subset: AIM; IM |
Affiliation:
|
Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA. rm2266@columbia.edu |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00433966 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Angioplasty, Transluminal, Percutaneous Coronary* / adverse effects Anticoagulants / adverse effects, therapeutic use* Female Follow-Up Studies Hemorrhage / chemically induced, epidemiology Heparin / adverse effects, therapeutic use Hirudins / adverse effects Humans Kaplan-Meiers Estimate Male Middle Aged Myocardial Infarction / drug therapy*, mortality Peptide Fragments / adverse effects, therapeutic use* Platelet Aggregation Inhibitors / adverse effects, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Proportional Hazards Models Recombinant Proteins / adverse effects, therapeutic use Stents / adverse effects Survival Rate Thrombosis / etiology, prevention & control Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin |
| Investigator | |
Investigator/Affiliation:
|
G W Stone / ; B R Brodie / ; D A Cox / ; C L Grines / ; B D Rutherford / ; D Bhatt / ; G Dangas / ; F Feit / ; M Ohman / ; A Colombo / ; G Guagliumi / ; E Garcia / ; E Grube / ; A Kastrati / ; H Bonnier / ; P Serruys / ; H Suryapranata / ; J Belardi / ; L Grinfeld / ; K Huber / ; L Rasmussen / ; E Grube / ; A Kastrati / ; Y Almagor / ; A Colombo / ; G Guagliumi / ; H Bonnier / ; H Suryapranata / ; D Nilsen / ; D Dudek / ; E Garcia / ; G Olivecrona / ; A Banning / ; S C Wong / ; M Farkouh / ; M Attubato / ; G Dangas / ; F Feit / ; R Mehran / ; D Target / ; J Tyson / ; D Winsted / ; R Mehran / ; I Bihl / ; H Parise / ; S J Pocock / ; B J Gersh / ; D Faxon / ; S King / ; D O Williams / ; A J Lansky / ; E Cristea / ; J Reiffel / ; G Mintz / ; Oscar A Mendiz / ; Jose Amadeo Alvarez / ; Jose Alvarez / ; Diego David Grinfeld / ; Cosme Argerich / ; Miguel Angel Riccitelli / ; Daniel Berrocal / ; Jorge Belardi / ; Anibal Agustin Damonte / ; Guillermo Cugat / ; A Rodriguez / ; Ernesto M Torresani / ; Hugo F Londero / ; Dietmar Glogar / ; Kurt Huber / ; George Gaul / ; Johann Altenberger / ; Othmar Pachinger / ; Hans-Georg Olbrich / ; Bernhard Witzenbichler / ; Martin Moeckel / ; Wolfgang Rutsch / ; Eberhard Grube / ; Gert Richardt / ; Klaus Pethig / ; Martin Desaga / ; Gerald Werner / ; Johannes Brachmann / ; Helmut Kuecherer / ; Rainer Hoffmann / ; Franz Hartmann / ; Stefan Willems / ; Jochen Wöhrle / ; Adnan Kastrati / ; Ricardo Krakover / ; Uri Rosenschein / ; Basil S Lewis / ; Morris Mosseri / ; Ran Petach-Tikva Kornowski / ; Luis Gruberg / ; Yaron Almagor / ; Victor Guetta / ; Ariel Finkelstein / ; Yoseph Rozenman / ; Giulio Guagliumi / ; Antonio Colombo / ; Hans Bonnier / ; Harry Suryapranata / ; Peter Smits / ; Jan Erik Nordrehaug / ; Dennis Nilsen / ; Adam Witkowski / ; Dariusz Dudek / ; Andrzej Rynkiewicz / ; Jan Z Peruga / ; Andrzej Ochala / ; Krzysztof Zmudka / ; Robert Gil / ; Pascual Bordes / ; Adrian Banning / ; Daniel Blackman / ; Magdi El-Omar / ; Adam De Belder / ; Ever Grech / ; Bernard Prendergast / ; Sarah Johnson / ; Brent McLaurin / ; Tommy Lee / ; Duane S Pinto / ; Joe Choo / ; Ronald Karlsberg / ; Louis A Cannon / ; Trilok Sharma / ; James Ritter / ; Leroy Rabbani / ; Pierre P Leimgruber / ; Ofsman Quintana / ; Joseph McGarvey / ; Oscar Aguilar / ; Henry Liberman / ; Jim Blankenship / ; Ali Razavi / ; Rajesh Dave / ; John Rashid / ; Joseph F Stella / ; Edmund Finkinski / ; Matthew Bach / ; Bruce Brodie / ; Mirle A Kellett / ; Ofsman Quintana / ; Ron Waksman / ; Robert Iwaoka / ; Gregory M Eaton / ; Keith Atassi / ; Michael Attubato / ; Raj Chandwaney / ; Bradley Evans / ; Oscar Aguilar / ; Henry Lui / ; David Rizik / ; John Griffin / ; Jason O Hall / ; Michael C Foster / ; Jorge A Hernandez / ; Noel Camba / ; Thomas LaLonde / ; Mahesh Bikkina / ; Barry Rutherford / ; Vibhuti Singh / ; John McPherson / ; Richard B Zelman / ; James B Hermiller / ; Kenneth S Korr / ; Christopher Metzger / ; Paul Gordon / ; Cary Hirsch / ; Venkatraman Srinivasan / ; Kalim Habet / ; Mark A Turco / ; Douglas Ebersole / ; Cindy L Grines / |
| Comments/Corrections | |
Comment In:
|
Lancet. 2010 Jan 30;375(9712):375
[PMID:
20113821
]
Lancet. 2009 Oct 3;374(9696):1125-7 [PMID: 19717183 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 ...
Next Document: Otamixaban in acute coronary syndromes.